Kelun-Biotech Phase III Trial Shows PFS Improvement in NSCLC
Kelun-Biotech said the OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival versus platinum doublet plus pembrolizumab in first-line patients with PD-L1 below 1% and EGFR/ALK-negative advanced non-squamous NSCLC. Overall survival trended in fa